Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 6 of 14

9. Monopar Therapeutics Inc (NASDAQ:MNPR)

Number of Hedge Fund Holders In Q3 2024: N/A

Monopar Therapeutics Inc (NASDAQ:MNPR) is a biotech company that is developing radiopharmaceuticals for oncology and a late-stage treatment for Wilson disease.

The stock is up markedly so far in 2025 due to Monopar securing global rights to develop and commercialize ALXN-1840. This is a Phase 3-ready drug for Wilson disease.

It currently has limited treatments, but this has the potential to address severe symptoms and has driven investor optimism.

The company raised capital with a $17.7 million offering in October 2024 and another $40 million offering in December 2024.

The consensus price target of $43 implies 0.54% upside.

MNPR stock is up 91.95% year-to-date.

Page 6 of 14